Evofem Biosciences, Inc.

Evofem Biosciences, Inc. logo
🇺🇸United States
Ownership
Public
Established
2009-01-01
Employees
51
Market Cap
$1M
Website
http://www.evofem.com

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

First Posted Date
2020-09-17
Last Posted Date
2024-01-30
Lead Sponsor
Evofem Inc.
Target Recruit Count
1892
Registration Number
NCT04553068
Locations
🇺🇸

Matrix Clinical Research, Los Angeles, California, United States

🇺🇸

Urgent Care Clinical Trials @City Doc Urgent Care-Inwood, Dallas, Texas, United States

🇺🇸

Planned Parenthood Southeastern Pennsylvania, Philadelphia, Pennsylvania, United States

and more 88 locations

AMP002 Phase III Contraceptive Study

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-08-09
Last Posted Date
2020-09-17
Lead Sponsor
Evofem Inc.
Target Recruit Count
1384
Registration Number
NCT03243305
Locations
🇺🇸

The Community Research of South Florida 167, Hialeah, Florida, United States

🇺🇸

Vital Pharma Research, Inc. 123, Hialeah, Florida, United States

🇺🇸

Mesa Obstetricians & Gynecologists 184, Mesa, Arizona, United States

and more 84 locations

Phase 2B/3 Double-blinded Placebo-controlled

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-04-11
Last Posted Date
2020-08-12
Lead Sponsor
Evofem Inc.
Target Recruit Count
860
Registration Number
NCT03107377
Locations
🇺🇸

University of Tennessee Medical Center, Knoxville, Tennessee, United States

🇺🇸

CityDoc Urgent Care, Dallas, Texas, United States

🇺🇸

Planned Parenthood Southeastern Pennsylvania, Philadelphia, Pennsylvania, United States

and more 47 locations

Duration of Effect of Acidform Gel on Vaginal pH

First Posted Date
2016-02-26
Last Posted Date
2020-11-20
Lead Sponsor
Evofem Inc.
Target Recruit Count
105
Registration Number
NCT02693418
Locations
🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

🇺🇸

Metro Health Medical Center, Cleveland, Ohio, United States

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2015-06-29
Last Posted Date
2019-12-10
Lead Sponsor
Evofem Inc.
Target Recruit Count
100
Registration Number
NCT02483533

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-03-25
Last Posted Date
2019-01-07
Lead Sponsor
Evofem Inc.
Target Recruit Count
793
Registration Number
NCT02398188
Locations
🇺🇸

Society Hill Dermatology, Philadelphia, Pennsylvania, United States

🇺🇸

Wake Research Associates, Raleigh, North Carolina, United States

🇺🇸

Zel Skin & Laser Specialist, LLC, Edina, Minnesota, United States

and more 32 locations

Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-03-01
Last Posted Date
2022-07-12
Lead Sponsor
Evofem Inc.
Target Recruit Count
3389
Registration Number
NCT01306331
Locations
🇺🇸

Wake Research Associates, Raleigh, North Carolina, United States

🇺🇸

University of Pennsylvania Medical Center, Reproductive Research Unit, Philadelphia, Pennsylvania, United States

🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 48 locations
© Copyright 2024. All Rights Reserved by MedPath